TD Private Client Wealth’s Kura Oncology KURA Stock Holding History

TD Private Client Wealth’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$953	Buy	+89	New	+$995	﹤0.01%	1534

Other funds holding KURA

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Alethea Capital Management Mercer Island, Washington $197M AUM 51.86% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

TD Private Client Wealth's KURA Position: Q3 2026 in Review

TD Private Client Wealth opened a new position in Kura Oncology (KURA) in Q3 2026: 89 shares worth $953. The stake represents ﹤0.01% of the portfolio and ranks #1534 among its holdings.

177 funds tracked by Wall St. Rank hold KURA as of Q3 2026.

TD Private Client Wealth held 89 shares of Kura Oncology worth $953 as of Q3 2026.
Kura Oncology was a new TD Private Client Wealth position in Q3 2026.
Kura Oncology made up ﹤0.01% of TD Private Client Wealth's portfolio in Q3 2026, its #1534 holding.
177 funds tracked by Wall St. Rank held Kura Oncology as of Q3 2026.

Based on TD Private Client Wealth's 13F filing for Q3 2026, filed 28 Oct 2026.